What is Bronchiectasis and Why is Epidemiology Forecasting Important?
Bronchiectasis is a chronic, progressive lung condition resulting in abnormal and permanent widening of the bronchi. This damage leads to mucus accumulation, chronic cough, and recurrent respiratory infections. Epidemiology forecasting is critical for understanding disease prevalence, incidence trends, treatment burden, and healthcare planning across different regions.
Currently, it is estimated that 350,000 to 500,000 adults are affected by bronchiectasis globally, with post-infective bronchiectasis being the most common type. Epidemiological patterns show higher prevalence in women (535/100,000) compared to men (467/100,000), with significant coexistence of asthma and COPD in 42% and 36% of cases, respectively.
The Bronchiectasis Epidemiology Forecast Report 2025–2034 provides an in-depth assessment of disease demographics, historical trends, and projections for the next decade across major geographies.
Bronchiectasis: Disease Overview
Bronchiectasis develops when the airway walls in the lungs are permanently scarred or thickened. This structural damage hampers the body’s ability to clear mucus, which accumulates and sets the stage for cycles of persistent inflammation and infection.
Common Symptoms:
- Chronic cough with thick, colored mucus
- Breathlessness or wheezing
- Frequent chest infections
- Fatigue
Common Causes:
- Severe respiratory infections (post-infective bronchiectasis)
- COPD and asthma (frequent comorbidities)
- Immune system deficiencies
- Conditions like cystic fibrosis
- Allergic bronchopulmonary aspergillosis
Bronchiectasis: Treatment Overview
While bronchiectasis has no definitive cure, treatment focuses on slowing progression, managing symptoms, and preventing flare-ups.
Standard Therapies
- Airway Clearance: Chest physiotherapy, oscillatory devices, and breathing exercises help mucus expulsion.
- Medications:
- Bronchodilators to ease airway constriction
- Mucolytics for thinning mucus
- Antibiotics (oral, inhaled, or IV) for managing infections
- Preventive Healthcare: Vaccinations against influenza and pneumonia reduce infection risk.
- Pulmonary Rehabilitation: Improves exercise capacity and lung efficiency.
Emerging and Investigational Therapies
- Brensocatib: A novel inhibitor of neutrophil serine proteases, showing promising results in reducing bronchiectasis exacerbations.
- BI1291583: Targets the respiratory microbiome to prevent airway bacterial colonization.
- Alpha 1-proteinase inhibitors: Being studied for reducing inflammatory airway damage.
- Advanced Inhalation Therapies: Next-generation nebulizers and inhalers for improved drug delivery.
- Surgical Options: Rarely considered, but may be used in severe localized disease.
Bronchiectasis Epidemiology Forecast Report Coverage
Expert Market Research’s “Bronchiectasis Epidemiology Forecast Report 2025–2034” provides comprehensive data on the historical (2018–2024) and projected (2025–2034) trends of bronchiectasis prevalence across major markets.
Report Highlights:
- Historical epidemiological trends across 2018–2024
- 2024 as the base year for assessments
- Forecast extending from 2025 to 2034
- Analysis of prevalence by gender, comorbidities, and age group
- Coexistence statistics with other respiratory diseases (COPD and asthma)
- Burden of post-infective bronchiectasis
Bronchiectasis Market Demographics
- Estimated Patients (2024): 350,000 – 500,000 adults
- By Gender:
- Females: 535 per 100,000
- Males: 467 per 100,000
- By Type:
- Post-infective bronchiectasis: Most common
- Other causes: Immune system disorders, genetic factors (e.g., cystic fibrosis)
- Comorbidities:
- Asthma: 42%
- COPD: 36%
Bronchiectasis Epidemiology: Regional Coverage
The report analyzes 8 major global markets (8MM):
- United States – Largest diagnosed patient pool, higher prevalence due to access to screenings
- Germany, France, Italy, Spain – Growing elderly population contributes to rising cases
- United Kingdom – High awareness and early diagnosis rates
- Japan – Significant aging demographic, rising COPD-linked bronchiectasis
- India – Rapidly growing diagnosis rates due to infections and underreported historical burden
Future Outlook of the Bronchiectasis Epidemiology
Over the next decade, the number of diagnosed bronchiectasis patients is projected to increase significantly due to better diagnostic imaging, aging populations, and improvements in awareness.
- Advancement in treatments: Novel therapies like brensocatib and BI1291583 will redefine the treatment landscape.
- Increased screening and awareness: Better clinical recognition will uncover previously undiagnosed cases.
- Rise in comorbidities: With asthma and COPD cases rising globally, the burden of bronchiectasis will intensify.
- Personalized medicine and AI: Predictive diagnostic tools and personalized therapy will improve disease management.
Browse More Reports
Healthcare Cloud Computing Market
Assisted Reproductive Technology Market
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
